Clinical Trial Detail

NCT ID NCT01524978
Title A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications

Advanced Solid Tumor

multiple myeloma

Therapies

Vemurafenib

Cetuximab

Age Groups: adult senior

Additional content available in CKB BOOST